Vaccine study for people waiting for liver transplant
Part of Digestive system clinical trials.
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You are waiting for a liver transplant and were referred for an infectious-disease (infection) consultation as part of the pre-transplant workup
- You have been told about the study and you agree to participate
- You should not be a candidate for a transplant of more than one organ
- You should not have taken strong immune-suppressing medicines recently (or certain cancer treatments) that could affect vaccine results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study develops a score to predict infection risk right after a liver transplant. It uses blood samples from transplant day to identify which patients are more likely to get infections, helping doctors tailor care.
This trial tests a new way to preserve donated livers before transplant, which may help people with severe liver disease get a transplant sooner. It may be an option for patients with certain cancers or urgent liver failure.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests two RSV vaccine schedules in people who have had a lung transplant or a stem cell transplant. It looks at whether the vaccines are safe and how well they boost the immune system against RSV, a common respiratory virus.
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
This trial tests an mRNA vaccine for people with liver cancer who are waiting for a liver transplant. The vaccine is given to help control the cancer while they wait.
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.